Skip to main content

Smith Stan's Form 4 filing

MAIA Biotechnology, Inc.MAIA · filed Dec 27, 2022

Accession no.
0001127602-22-028285
Filed
Dec 27, 2022
Trade date
Dec 22-23, 2022
Filing delay
5 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 2 non-derivative transactions. Open-market purchases total $5.83K. It was filed 5 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Smith StanCIK 0001913199Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 22, 2022Common StockPPurchaseAcquired+731$3.34F1,F2+$2,441.54508,506Indirect
Dec 23, 2022Common StockPPurchaseAcquired+981$3.45F1,F3+$3,384.45509,487Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

Referenced by the price of 2 transactions in Table I.

F2

The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.25 to $3.42, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

Referenced by the price of 1 transaction in Table I.

F3

The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.35 to $3.50, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)